
Hormone Optimization Enhances PDE5 Inhibitor Efficacy in Hypogonadal Men with ED
Reading Time: 2 minutes Introduction Phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil and tadalafil, are cornerstone treatments for erectile dysfunction (ED). However, a subset of men, particularly those with hypogonadism, may experience resistance to these medications. This article explores the outcomes of hormone optimization in hypogonadal men resistant to PDE5 inhibitors, with a specific focus on improving sexual dysfunction. Understanding Hypogonadism and PDE5 Inhibitor Resistance Hypogonadism, characterized by low testosterone levels, can significantly impact sexual health, contributing to ED and reduced libido. In hypogonadal men, the efficacy of PDE5 inhibitors may be compromised due to the intricate relationship between testosterone and nitric oxide...